We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TransMedics (TMDX) Receives FDA Nod for OCS Heart System
Read MoreHide Full Article
TransMedics Group, Inc. (TMDX - Free Report) recently announced its receipt of the FDA’s premarket approval of its OCS Heart System for use with organs from donors after brain death (“DBD”). The system is indicated for the preservation of DBD donor hearts that are considered unsuitable for procurement and transplantation at the time of initial evaluation, based on limitations of extended cold static cardioplegic preservation.
For investors’ note, the indication is on the basis of the results of the OCS Heart EXPAND Trial, the associated OCS Heart EXPAND Continued Access Protocol and the OCS Heart PROCEED II Trial.
The latest FDA clearance is expected to significantly solidify TransMedics’ foothold in the U.S. heart transplantation space.
Significance of the Approval
Per management, the regulatory nod for its OCS Heart System is expected to provide access to its OCS technology for helping more heart transplant patients in the United States. Following the clearance, the OCS Heart System has become the only FDA-approved device indicated for ex-vivo perfusion and assessment of both donor hearts and lungs as an alternative to the antiquated cold storage preservation.
The company is currently working toward the next phase of its commercial activities, the initiation of the OCS Heart Perfusion Registry and potentially expanding its future clinical indications.
Per an expert associated with the OCS Heart EXPAND Trial, the system enables real-time assessment of the donor heart's viability and lowers the adverse effects of cold storage. This is likely to increase the utilization of donor hearts that are rarely used due to limitations of cold storage preservation. This will expand the donor pool of acceptable hearts and help the company meet the surging demand in the United States for heart transplantation.
Industry Prospects
Per a report by ReportLinker, the global heart transplant market was estimated to be $9,077.71 million in 2020 and is projected to reach $15,813.98 million by 2026 at a CAGR of approximately 9.7%. Factors like rising frequency of coronary artery diseases and heart failure cases, as well as increasing number of elderly population and patients with high blood cholesterol level, are expected to drive the market.
Given the market potential, the FDA’s approval is likely to provide a significant boost to TransMedics’ business globally.
Notable Developments
Of late, TransMedics has witnessed a few notable developments across its business.
In August, the company reported robust second-quarter 2021 results, driven by an increase in sales of OCS Lung and Heart disposable sets in the United States and internationally.
TransMedics, in July, announced the receipt of the FDA’s 510(k) clearance of its OCS Lung Solution for use in transplants using cold-storage techniques.
In June, the company announced favorable and complete results of the OCS Liver PROTECT Trial (PROTECT).
Price Performance
Shares of TransMedics have gained 87.4% in the past year compared with the industry’s 18.2% growth and the S&P 500's 34.9% rise.
Image Source: Zacks Investment Research
Zacks Rank & Stocks to Consider
Currently, TransMedics carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are Henry Schein, Inc. (HSIC - Free Report) , IDEXX Laboratories, Inc. (IDXX - Free Report) and Intuitive Surgical, Inc. (ISRG - Free Report) .
Image: Bigstock
TransMedics (TMDX) Receives FDA Nod for OCS Heart System
TransMedics Group, Inc. (TMDX - Free Report) recently announced its receipt of the FDA’s premarket approval of its OCS Heart System for use with organs from donors after brain death (“DBD”). The system is indicated for the preservation of DBD donor hearts that are considered unsuitable for procurement and transplantation at the time of initial evaluation, based on limitations of extended cold static cardioplegic preservation.
For investors’ note, the indication is on the basis of the results of the OCS Heart EXPAND Trial, the associated OCS Heart EXPAND Continued Access Protocol and the OCS Heart PROCEED II Trial.
The latest FDA clearance is expected to significantly solidify TransMedics’ foothold in the U.S. heart transplantation space.
Significance of the Approval
Per management, the regulatory nod for its OCS Heart System is expected to provide access to its OCS technology for helping more heart transplant patients in the United States. Following the clearance, the OCS Heart System has become the only FDA-approved device indicated for ex-vivo perfusion and assessment of both donor hearts and lungs as an alternative to the antiquated cold storage preservation.
The company is currently working toward the next phase of its commercial activities, the initiation of the OCS Heart Perfusion Registry and potentially expanding its future clinical indications.
Per an expert associated with the OCS Heart EXPAND Trial, the system enables real-time assessment of the donor heart's viability and lowers the adverse effects of cold storage. This is likely to increase the utilization of donor hearts that are rarely used due to limitations of cold storage preservation. This will expand the donor pool of acceptable hearts and help the company meet the surging demand in the United States for heart transplantation.
Industry Prospects
Per a report by ReportLinker, the global heart transplant market was estimated to be $9,077.71 million in 2020 and is projected to reach $15,813.98 million by 2026 at a CAGR of approximately 9.7%. Factors like rising frequency of coronary artery diseases and heart failure cases, as well as increasing number of elderly population and patients with high blood cholesterol level, are expected to drive the market.
Given the market potential, the FDA’s approval is likely to provide a significant boost to TransMedics’ business globally.
Notable Developments
Of late, TransMedics has witnessed a few notable developments across its business.
In August, the company reported robust second-quarter 2021 results, driven by an increase in sales of OCS Lung and Heart disposable sets in the United States and internationally.
TransMedics, in July, announced the receipt of the FDA’s 510(k) clearance of its OCS Lung Solution for use in transplants using cold-storage techniques.
In June, the company announced favorable and complete results of the OCS Liver PROTECT Trial (PROTECT).
Price Performance
Shares of TransMedics have gained 87.4% in the past year compared with the industry’s 18.2% growth and the S&P 500's 34.9% rise.
Image Source: Zacks Investment Research
Zacks Rank & Stocks to Consider
Currently, TransMedics carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are Henry Schein, Inc. (HSIC - Free Report) , IDEXX Laboratories, Inc. (IDXX - Free Report) and Intuitive Surgical, Inc. (ISRG - Free Report) .
Henry Schein’s long-term earnings growth rate is estimated at 13.9%. The company presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
IDEXX’s long-term earnings growth rate is estimated at 19.9%. It currently has a Zacks Rank #2.
Intuitive Surgical’s long-term earnings growth rate is estimated at 9.7%. It currently carries a Zacks Rank #2.